Pharmasintez plans to produce up to 5 million doses of Sputnik V vaccine monthly


Pharmasintez Group of Companies plans to produce from 4 to 5 million doses of the Sputnik V coronavirus vaccine every month in the second half of 2021, said Vikram Punia, president of the Pharmasintez group of companies, in an interview with RBC.

“I hope that in May we will get the registration of the site for the production of the vaccine and by this time we will start to produce quite a lot, and in general the so-called industrial scale at 4-5 million doses per month, I believe that it will be the III-IV quarter,” TAAS quoting Punia.

According to him, the first batch of the vaccine has already been received and at the moment its revised version is being validated. Punia also expressed the hope that by the fall in Russia resources will release 15-20 million doses monthly and in 2022 the need for the vaccine will be completely closed.

“As long as there is a need for this, we will make a vaccine,” he stressed.

On November 3, an agreement was signed on the transfer of technological documentation with the Gamalei National Research Center for Epidemiology and Microbiology. The site for the production of the first Russian vaccine against the Sputnik V COVID-19 was chosen the Pharmasintez-Nord plant in St. Petersburg.